Form 4: Amgen CEO Robert Bradway Reports Stock Disposal to Cover Tax Obligations

Amgen's CEO, Robert Bradway, disposed of 2,294 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• On May 2, 2024, Robert A. Bradway, the Chairman, CEO, and President of Amgen Inc., disposed of 2,294 shares of Amgen common stock.
• The transaction was executed to cover tax obligations associated with the vesting of Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $277.37 per share.
• Following the transaction, Bradway directly owns 659,501 shares of Amgen common stock, which includes vested and unvested RSUs and dividend equivalents.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing an insider transaction. It doesn't convey strong positive or negative sentiment, but rather provides factual information about stock disposal for tax purposes. Therefore, a neutral score is appropriate.

Future Outlook

The document does not contain specific forward-looking statements about Amgen's future performance, but it does detail the vesting schedule for Bradway's RSUs.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives who receive stock-based compensation. It provides transparency into the trading activities of key personnel at Amgen.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units (RSUs) as a significant component.
• Companies like Johnson & Johnson, Pfizer, and Merck also utilize RSUs as part of their executive compensation plans.
• The vesting schedules and tax implications associated with these RSUs are standard across the industry.
• The number of shares disposed of by Bradway is relatively small compared to his overall holdings, suggesting this was primarily for tax purposes rather than a strategic divestment.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders, as it is a routine disposal of shares for tax purposes.
• The filing provides transparency to stakeholders regarding the stock ownership of Amgen's CEO.

Key Dates